Loading...
Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Table of Content

    Volume 31 Issue 9
    26 September 2026
    Gastrodin attenuates 6-hydroxydopamine-induced apoptosis in PC12 cells by modulating the PI3K signaling pathway and reducing reactive oxygen species levels
    Xinyu ZHANG, Shaowen WEN, Fei ZHAO, Lili WU, Jionglu ZHANG, Zehai FANG, Hongjie LIU
    2026, 31(9):  1153-1161.  doi:10.12092/j.issn.1009-2501.2026.09.001
    Asbtract ( 47 )   HTML ( 1)   PDF (7265KB) ( 9 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the potential therapeutic mechanisms of Gastrodia elata and its main active component gastrodin (GSD) in Parkinson's disease (PD), focusing on apoptosis, oxidative stress, and the PI3K/Akt/mTOR signaling pathway. METHODS: A 6-hydroxydopamine (6-OHDA)-induced PC12 cell damage model was used to evaluate the effects of GSD on cell apoptosis, intracellular reactive oxygen species (ROS) levels, and the expression of PI3K/Akt/mTOR signaling pathway-related proteins in vitro. RESULTS: GSD significantly attenuated 6-OHDA-induced apoptosis in PC12 cells and modulated the activity of the PI3K signaling pathway. In addition, GSD effectively reduced intracellular ROS levels, and this effect was independent of PI3K pathway regulation. CONCLUSION: Gastrodin may exert neuroprotective effects by reducing intracellular ROS levels and modulating the PI3K/Akt/mTOR signaling pathway, thereby alleviating 6-OHDA-induced apoptosis in PC12 cells. These findings provide experimental evidence supporting the potential application of GSD in PD therapy.

    Mechanism of stem cell exosome-mediated repair of hepatocyte injury via mitochondrial and fatty acid metabolism
    Xinxin YIN, Changpeng XIE, Xuejing LI, Liping ZHANG, Zhanhai SU, Haiyan WANG, Qiong WU, Yuanming PAN, Juan AN
    2026, 31(9):  1162-1172.  doi:10.12092/j.issn.1009-2501.2026.09.002
    Asbtract ( 377 )   HTML ( 0)   PDF (4461KB) ( 6 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the metabolic mechanism by which umbilical cord mesenchymal stem cell exosomes repair CCl4-induced acute liver injury and to analyze the role of key metabolites in regulating the repair process. METHODS: The experiment was divided into three groups: the CCl4 group, the CCl4+low-dose exosome group, and the CCl4+high-dose exosome group. Cell viability of HL-7702 cells, as well as levels of AST, ALT, and MDA, were measured. Targeted metabolomics analysis was performed to identify differential metabolites between the CCl4 group and the CCl4+exosome group. The co-localization relationship between exosomes and the nucleus or mitochondria in HL-7702 cells was observed using confocal laser scanning microscopy. Mitochondrial structural changes in each group were examined by transmission electron microscopy. RESULTS: Exosomes significantly reversed the decline in cell viability induced by 25 mmol/L CCl4. Additionally, exosomes markedly reduced AST, ALT, and MDA levels. A total of 73 significantly differential metabolites were identified between the CCl4 group and the CCl4+exosome group, including glycodeoxycholic acid and tetradecanedioic acid. Fluorescence staining revealed co-localization of exosomes with both the nucleus and mitochondria. CONCLUSION: Exosomes significantly reversed the abnormal levels of AST, ALT, and MDA induced by CCl4 in HL-7702 cells and protected mitochondrial structure against oxidative stress damage. Metabolomic findings suggest that exosomes may repair hepatocyte injury by mediating mitochondrial function and fatty acid metabolism.

    Study on the mechanism of astragaloside IV in pelvic floor dysfunction rats by regulating the miR-340-5p and SMAD2 expression
    Jie LI, Zhanli WANG, Yao HUANG, Xia JI
    2026, 31(9):  1173-1181.  doi:10.12092/j.issn.1009-2501.2026.09.003
    Asbtract ( 24 )   HTML ( 1)   PDF (6679KB) ( 6 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the protective effect of astragaloside IV (ASIV) in pelvic floor dysfunction (PFD) rats and its effect on the expression of microRNA (miR)-340-5p and Smad homolog 2 (SMAD2). METHODS: PFD rat model was constructed. The successfully modeled rats were randomly divided into the PFD group, the ASIV-L group, the ASIV-M group, the ASIV-H group, the ASIV-H+miR-NC group, and the ASIV-H+miR-340-5p mimics group, with 12 rats in each group. Another 12 normal healthy rats were taken as the Control group. The relevant indicators such as pelvic floor function, urodynamics (bladder volume, intravesical pressure, leak point pressure), and mean myoelectric potential of muscle fibers of rats in each group were detected. HE staining and Masson staining were used to observe the pathological changes of the levator ANI muscle tissue. Immunohistochemical detection of the relative expressions of type Ⅰ Collagen (Collagen Ⅰ) and Elastin. qRT-PCR was used to detect the level of miR-340-5p. Western blot was used to detect the relative expression of SMAD2. The dual-luciferase reporter gene system was used to verify the targeting relationship between miR-340-5p and SMAD2. RESULTS: Compared with the Control group, the levator ani muscle in the PFD group exhibited hypertrophy, with atrophied cells and the presence of mast cells within the muscle fiber tissue. A large number of muscle fibers showed necrosis and disorganized arrangement. A small amount of blue collagen fibers was observed, and the overall muscle fiber content was significantly reduced (P<0.05). Bladder volume, intravesical pressure, leak point pressure, vaginal resting pressure, vaginal squeeze pressure, and the mean myoelectric potential of type Ⅰ and type Ⅱ muscle fibers were all decreased (P<0.05). The relative expressions of Collagen Ⅰ, Elastin, and protein SMAD2 were also decreased, while the bladder neck range of motion, urethral rotation angle, and relative level of miR-340-5p were increased (P<0.05). Compared with the PFD group, the ASIV-L, ASIV-M, ASIV-H, and ASIV-H+miR-340-5p mimics groups showed markedly improvements in muscle fiber tissues, with reduced necrosis, no apparent degeneration, and more orderly arranged fibers. Collagen fiber content increased to varying degrees, and the overall muscle fiber content was elevated (P<0.05). Bladder volume, intravesical pressure, leak point pressure, vaginal resting pressure, vaginal squeeze pressure, and the mean myoelectric potential of type Ⅰ and type Ⅱ muscle fibers were increased (P<0.05). The relative expressions of Collagen Ⅰ, Elastin and SMAD2 were also upregulated, whereas the bladder neck range of motion, urethral rotation angle, and relative level of miR-340-5p were decreased (P<0.05). In the ASIV-H+miR-340-5p mimics group, muscle fiber histopathological damage was more severe than in the ASIV-H, and ASIV-H+miR-NC groups, with a significant reduction in collagen fibers. Bladder volume, intravesical pressure, leak point pressure, vaginal resting pressure, vaginal squeeze pressure, and the mean myoelectric potential of type Ⅰ and type Ⅱ muscle fibers were decreased (P<0.05). The relative expressions of Collagen Ⅰ, Elastin and SMAD2 were decreased, while the bladder neck range of motion, urethral rotation angle and relative level of miR-340-5p were increased (P<0.05). Analysis using the Starbase database and dual-luciferase gene report assays indicated that miR-340-5p targeted and inhibited SMAD2 expression. CONCLUSION: ASIV improves PFD in rats through downregulation of miR-340-5p and upregulation of SMAD2.

    Dioscin attenuates UUO-induced renal fibrosis by inhibiting the Akt/GSK-3β signaling pathway
    Junwei GAO, Guijie MA, Xiaomeng LIN, Yingping DENG, Chengqian YIN, Chenguang WU, Peng LIU, Guanghui ZHONG
    2026, 31(9):  1182-1192.  doi:10.12092/j.issn.1009-2501.2026.09.004
    Asbtract ( 9 )   HTML ( 1)   PDF (8555KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the effect of dioscin (Dis) on unilateral ureteral obstruction (UUO)-induced renal fibrosis and on transforming growth factor-β1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT)-like phenotypic changes in human renal tubular epithelial (HK-2) cells, as well as its underlying mechanism. METHODS: Male C57BL/6J mice were randomly divided into sham-operated, UUO, UUO+Dis (50 mg/kg), and UUO+Dis (100 mg/kg) groups. After 7 days of intervention, kidney tissues were collected for hematoxylin-eosin and Masson's trichrome staining to observe histopathological changes. Immunohistochemistry, Western blot, and real-time PCR (RT-PCR) were used to detect the expression of protein kinase B (Akt)/glycogen synthase kinase 3β (GSK-3β) pathway and EMT-related molecules. HK-2 cells were induced with TGF-β1 to establish an EMT-like phenotypic changes model and treated with Dis and/or the Akt agonist SC79 for 24 h. Western blot, immunofluorescence, and RT-PCR were performed to evaluate the above indicators. RESULTS: Dis significantly ameliorated renal pathological injury and collagen deposition in UUO mice. It inhibited the phosphorylation of Akt and GSK-3β in UUO kidneys (P<0.05), downregulated the expression of fibronectin, α-smooth muscle actin (α-SMA), and Vimentin (P<0.05), and upregulated E-cadherin expression (P<0.05). In HK-2 cells, Dis suppressed TGF-β1-induced phosphorylation of Akt/GSK-3β (P<0.01) and reversed the upregulation of α-SMA and Vimentin (P<0.01). Furthermore, SC79 activated this pathway and aggravated TGF-β1-induced EMT-like phenotypic changes (P<0.05), whereas Dis reversed these effects of SC79 (P<0.01). CONCLUSION: Dis may alleviate UUO-induced renal fibrosis and TGF-β1-induced EMT-like phenotypic changes by inhibiting the overactivation of the Akt/GSK-3β signaling pathway.

    Evocalcet derivative attenuates diabetic osteoporosis and promotes osteogenesis
    Meixuan CHEN, Kai LIU, Yuan XU, Yuan HUA, Yixun GUO, Kai ZHANG, Yan ZHANG
    2026, 31(9):  1193-1199.  doi:10.12092/j.issn.1009-2501.2026.09.005
    Asbtract ( 22 )   HTML ( 0)   PDF (3916KB) ( 9 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To evaluate the ameliorative effect of calcium-sensing receptor (CaSR) agonist evocalcet derivative on osteoporosis in diabetic mice and its stimulative effect on osteogenesis. METHODS: The C57BL/6 mice were randomly divided into a normal control group, a model group, and an evocalcet derivative group. A type 2 diabetes mellitus (T2DM) mouse model was established by a high-fat diet combined with intraperitoneal injection of low-dose streptozotocin (30 mg/kg). The mice in the treatment group were daily administered with an evocalcet derivative (0.6 mg/kg, i.g.) in 0.5% CMC-Na solution, while the mice in other groups were administered with an equal volume of 0.5% CMC-Na solution for 6 weeks. During the administration period, the body weight and the fasting blood glucose levels of the mice were dynamically monitored at 2-week intervals. Serum calcium (Ca) and phosphorus (Pi) levels were measured in each group. Micro-CT was used to detect bone mineral density and bone microstructure, and a three-point bending biomechanics test was performed to detect the mechanical parameters at the mid-shaft of the mice femur. HE staining and ALP staining were respectively used to detect bone histomorphology and osteoblasts, and Western blot was carried out to measure the protein expression of CaSR downstream molecules and osteogenic-related molecules. RESULTS: After intervention with an evocalcet derivative, serum Ca and Pi levels in mice were significantly reduced (P<0.05). Micro-CT showed a significant increase in bone mineral density (P<0.05) and in trabecular thickness (P<0.05), and a significant decrease in trabecular bone separation (P<0.001); moreover, the area percentage of trabecular bone was dramatically enhanced (P<0.05) at the proximal end of the mice tibia. Biomechanical tests showed a significant elevation in maximum load, maximum deformation, and elastic deformation (P<0.05) at the diaphysis of the mice femur. As compared to the model group, the drug treatment induced a significant increase (P<0.01) in the number of osteoblasts. The Western blot results showed that the evocalcet derivative elevated the expression ratio of p-ERK/ERK (P<0.001) and up-regulated protein expression (P<0.05) of Runx2 and COL-Ⅰ in the bone tissue of T2DM mice. CONCLUSION: The new generation calcimimetic agent evocalcet derivative could directly act on CaSR in bone, followed by stimulating its downstream ERK/Runx2/COL-Ⅰ signaling pathway, thereby improving diabetic osteoporosis by exerting its osteogenic effect.

    Cuiru Keli improves bromocriptine-induced postpartum hypogalactia in rats by regulating the WTAP-Wnt5a-β-catenin signaling axis
    Hui LI, Qiuyun XUE, Meiling YUAN, Qiying JIN, Jiaqing CHEN, Aixin XIA, Chenhao XU, Chenggui MIAO
    2026, 31(9):  1200-1213.  doi:10.12092/j.issn.1009-2501.2026.09.006
    Asbtract ( 6 )   HTML ( 0)   PDF (3535KB) ( 3 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To study the effect and mechanism of Cuiru Keli (CRKL) on bromocriptine-induced postpartum hypogalactia in rats. METHODS: ELISA was used to detect the level of prolactin (PRL) in mammary tissue (MT) of postpartum hypogalactia. Cultivate rat mammary epithelial cells (RMECs) in vitro. The effect of CRKL on RMEC proliferation was detected by CCK8 method to determine the drug-containing serum. RT-qPCR and immunofluorescence detection of lactose, milk fat, and milk protein related gene expression. Network pharmacology predicts the signaling pathway of CRKL treatment for postpartum hypogalactia. Molecular docking and molecular dynamics verification of the binding between key components of CRKL and WTAP. RIP was used to study the interaction between WTAP and Wnt5a. RT-qPCR and Western blot were used to investigate the regulatory mechanism of CRKL on the Wnt/β-catenin signaling pathway. RESULTS: CRKL significantly increased the hourly milk production of female rats (P<0.05 or P<0.01). CRKL increases PRL levels in MT of model rats (P<0.01). Serum containing CRKL promotes the expression of PRLR, FASN, CSN2, and GLUT1 (all P<0.05 or P<0.01). Network pharmacology predicts a high correlation between the Wnt/β-catenin signaling pathway and CRKL treatment for postpartum hypogalactia. And the serum containing CRKL promotes the expression of key genes CCND1, c-Myc, and β-catenin in the Wnt signaling pathway (all P<0.05 or P<0.01). Molecular docking and molecular dynamics indicate that the key component of CRKL has strong binding ability with WTAP. Overexpression of WTAP in RMECs interferes with the function of CRKL (P<0.01). CONCLUSION: CRKL improves bromocriptine-induced postpartum hypogalactia in rats through the WTAP-Wnt5a-β-catenin signaling axis.

    Mechanistic study of paeoniflorin in ameliorating lacrimal gland inflammatory injury associated with Sjögren's syndrome
    Xuemei HAN, Hua ZHOU, Chunzi LIU
    2026, 31(9):  1214-1220.  doi:10.12092/j.issn.1009-2501.2026.09.007
    Asbtract ( 14 )   HTML ( 0)   PDF (5497KB) ( 7 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To preliminarily predict the potential action direction of paeoniflorin in alleviating lacrimal gland inflammatory injury associated with Sj?gren's syndrome (SS) based on target screening and pathway analysis, and to provide preliminary validation through molecular docking and animal experiments. METHODS: Candidate targets of paeoniflorin and SS were screened from public databases and subjected to pathway enrichment analysis to identify inflammation-related signaling directions. Molecular docking was then performed to evaluate the binding characteristics between paeoniflorin and key inflammatory proteins. An SS-related dry eye model was established in male NOD/ShiLtJ mice, which were treated with different doses of paeoniflorin or hydroxychloroquine for four weeks. Tear secretion was measured to assess lacrimal gland function. Histopathological changes were evaluated by hematoxylin–eosin (HE) staining, and the expression levels of inflammatory mediators and signaling proteins in lacrimal glands were determined using RT-qPCR and western blot. RESULTS: Pathway analysis indicated that inflammasome-related signaling, particularly the NOD-like receptor pathway, may be involved in the action of paeoniflorin. Molecular docking showed that paeoniflorin exhibited favorable binding affinity to NLRP3 and Caspase-1. Animal experiments indicated that paeoniflorin treatment improved tear secretion, alleviated lacrimal gland inflammatory infiltration and tissue injury in SS mice, and was accompanied by reduced expression levels of IL-6, IL-18, IL-1β, TNF-α, NLRP3, and Caspase-1. CONCLUSION: This study provides preliminary evidence that paeoniflorin may ameliorate SS-related lacrimal gland inflammatory injury, possibly through modulation of inflammatory responses and NLRP3/Caspase-1–related processes.

    Influencing factors of the first serum concentration of vancomycin in patients with peritoneal dialysis-related peritonitis
    Yumeng JIANG, Jianzhong LI, Yongfu HANG, Youjing YANG, Shasha TAO, Kun HU, Deyu XU, Guoyuan LU
    2026, 31(9):  1221-1230.  doi:10.12092/j.issn.1009-2501.2026.09.008
    Asbtract ( 13 )   HTML ( 0)   PDF (1079KB) ( 8 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the factors influencing the first serum concentration of vancomycin and its relationship to clinical efficacy in patients with peritoneal dialysis-related peritonitis (PDRP) receiving intraperitoneal administration. METHODS: We collected clinical data from 37 PDRP patients treated at The First Affiliated Hospital Of Soochow University between January 2021 and August 2024. All patients received 1 g intraperitoneal vancomycin and underwent serum concentration monitoring. Blood samples were drawn 0.5 h before the second dose to determine the first serum concentration. RESULTS: Seventeen patients with a prior history of peritonitis had a significantly higher first serum concentration [11.22(9.46,11.93) μg/mL] than 20 patients without such history [8.66(7.84,9.51) μg/mL; P<0.01]. Logistic regression identified that both prior peritonitis history and dosing interval duration were independent factors affecting the first serum concentration (P<0.01). A history of peritonitis elevates the first serum concentration at any dosing interval, whereas dosing interval significantly impacts concentrations only in patients without such a history. Before and after vancomycin treatment, there was no significant difference between the high-concentration group and the low-concentration group in the cell components of peritoneal fluid or time to negative culture conversion (P>0.05). Both groups showed significant reductions in the cell components of peritoneal fluid and C-reactive protein (CRP) levels post-treatment compared to baseline (P<0.05). Post-treatment CRP levels were significantly lower in the low-concentration group than in the high-concentration group (P<0.05). CONCLUSION: A history of prior peritonitis and the length of the dosing interval significantly affect the first serum concentration of intraperitoneal vancomycin in PDRP patients; However, the absolute first serum concentration level does not appear to influence clinical efficacy or time to culture negativity.

    Equivalence study of dapagliflozin metformin extended-release tablets in healthy subjects in China
    Xi YE, Yiqiao LIU, Xuanyu WU, Yiqi WANG, Fan LI, Hongyu LI, Xiangyun MENG, Fengling WANG
    2026, 31(9):  1231-1237.  doi:10.12092/j.issn.1009-2501.2026.09.009
    Asbtract ( 11 )   HTML ( 0)   PDF (652KB) ( 3 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To compare the bioavailability and bioequivalence of dapagliflozin and metformin extended-release tablets in healthy Chinese subjects. METHODS: Plasma concentrations of dapagliflozin and metformin were determined using HPLC-MS/MS. Bioequivalence was analyzed using WinNonlin software (version 8.2) and SAS 9.4. RESULTS: Fasting conditions: After a single oral dose of the test or reference formulation (10 mg/1 000 mg dapagliflozin/metformin ER), the geometric mean ratios (90% confidence intervals) for dapagliflozin were Cmax: 109.18% (101.89%-116.99%); AUC0–t: 102.17% (99.37%-105.04%); AUC0–∞: 101.92% (98.94%-104.99%). For metformin the values were Cmax: 101.85% (96.67%-107.30%); AUC0–t: 100.51% (95.36%-105.95%); AUC0–∞: 100.03% (94.94%-105.39%). Fed conditions: After a single oral dose of the test or reference formulation, the geometric mean ratios (90% confidence intervals) for dapagliflozin were Cmax: 98.27% (88.80%-108.74%), AUC0–t: 103.09% (99.17%-107.16%); AUC0–∞: 103.27% (99.25%-107.45%). For metformin, the values were Cmax: 101.81% (98.36%-105.38%), AUC0–t: 98.99% (94.45%-103.75%), AUC0–∞: 98.94%(94.48%-103.61%). CONCLUSION: The two formulations are bioequivalent under both fasting and fed conditions.

    Correlation analysis between tigecycline therapeutic concentration monitoring and adverse reactions
    Shiya WU, Xiaodan LIU, Yan HU, Qi LIN
    2026, 31(9):  1238-1248.  doi:10.12092/j.issn.1009-2501.2026.09.010
    Asbtract ( 9 )   HTML ( 0)   PDF (949KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To establish a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of tigecycline in human plasma, which was used to study the pharmacokinetic profile in patients and to investigate the correlation between its blood concentration and drug-induced hepatic injury and coagulation dysfunction. METHODS: Plasma was processed by protein precipitation, separated on an Eclipse Plus C18 column, eluted by a 0.1% formic acid water-methanol gradient, with Reserpine as an internal standard, at a flow rate of 0.3 mL/min and detected in the positive ion mode and examined the method properties. Subsequently, clinical data with plasma samples were collected from patients using tigecycline between June 2024 and June 2025 (n=72). The groups were grouped according to whether or not an adverse reaction (ADR) occurred, the differences in blood concentrations between the two groups were compared, and the blood concentration breakpoints at which ADRs occurred were determined using subject's work characterization curve (ROC) analysis, and the sensitivity, specificity, and area under the curve (AUC) were calculated. RESULTS: The linear range of the proposed method was 50-5000 ng/mL, and the precision, accuracy and stability values were less than 10%, which met the requirements of clinical testing. The ROC curve showed that the fold point of tigecycline causing liver injury was 515.34 ng/mL, and that of coagulation dysfunction was 243.59 ng/mL. CONCLUSION: The HPLC-MS/MS of tigecycline in human plasma was successfully established, and the tigecycline blood concentration is related to the cause of liver injury and coagulation dysfunction. It is recommended that blood concentration monitoring combined with liver function and coagulation indicators should be applied clinically to ensure medication safety.

    Evidence-based progress and future therapeutic directions of myosin inhibitor aficamten—from mechanistic exploration to clinical practice
    Qi WANG, Yunzeng ZOU
    2026, 31(9):  1249-1255.  doi:10.12092/j.issn.1009-2501.2026.09.011
    Asbtract ( 7 )   HTML ( 0)   PDF (1307KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy, in which patients with the obstructive form (oHCM) face an elevated risk of heart failure and arrhythmias due to left ventricular outflow tract (LVOT) obstruction. Traditional drug therapies primarily aim to alleviate symptoms and are often unable to reverse the pathophysiological progression of the disease. The advent of cardiac myosin inhibitors (CMIs) marks the entry of HCM treatment into a new era of targeted intervention addressing the core disease mechanism. With its unique pharmacokinetic profile—such as a short half-life and low risk of drug-drug interactions—along with outstanding efficacy and safety, Aficamten has been demonstrated in multiple key clinical trials to significantly improve exercise capacity, symptoms, and quality of life in patients with oHCM, while also showing potential for reversing cardiac remodeling. This article systematically reviews the mechanism of action, pharmacological properties, clinical development history of Aficamten, and its position within the HCM treatment landscape, and offers perspectives on future research directions for personalized therapy and disease-modifying effects.

    Research progress of plasmalogen in Alzheimer's disease
    Yinan JIN, Wenjing LI, Lihua BIAN, Jianyou GUO
    2026, 31(9):  1256-1264.  doi:10.12092/j.issn.1009-2501.2026.09.012
    Asbtract ( 5 )   HTML ( 0)   PDF (1599KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex pathogenesis and limited current treatment options, urgently requiring new intervention targets. Plasmalogen, a naturally occurring glycerophospholipid, is widely distributed in cell membranes (such as myelin sheaths) and certain foods (such as seafood). Not only do they exhibit significant anti-inflammatory and antioxidant activities, but they have also been demonstrated to participate in memory enhancement. Growing evidence indicates that reduced plasmalogens levels are closely associated with the onset and progression of AD. Plasmalogens can target multiple key mechanisms to intervene in AD pathological processes, including clearing amyloid-β (Aβ) deposits, inhibiting apoptosis, promoting neurogenesis, and reducing excessive activation of microglia, thereby exerting neuroprotective effects. Therefore, supplementing with plasmalogens holds promise as a novel strategy for preventing and treating AD. This article aims to summarize and explore the latest research advances on plasmalogens in AD pathogenesis and therapeutic interventions, with the goal of providing new directions for further AD research and treatment.

    Research progress of transcription factor Bach1 in lung diseases
    Ai MA, Xiaofeng LI, Xiaoju LIU
    2026, 31(9):  1265-1274.  doi:10.12092/j.issn.1009-2501.2026.09.013
    Asbtract ( 8 )   HTML ( 0)   PDF (2629KB) ( 5 )  
    Figures and Tables | References | Related Articles | Metrics

    BTB and CNC homology 1 (Bach1), a crucial transcriptional repressor within the basic leucine zipper protein family, is ubiquitously expressed across various mammalian tissues. It plays significant roles in key biological processes such as oxidative stress, heme metabolism, ferroptosis, angiogenesis, vascular remodeling, epigenetic modification, glycolysis and mitochondrial function. This article primarily reviews the research progress of Bach1 in lung diseases, aiming to provide new insights for further investigation into its regulatory mechanisms and to explore its potential value as a therapeutic target.

    Research progress on endocrine-regulating mechanisms and active components of classical prescriptions in the treatment of hypertension
    Shuling SHAO, Jiawen WU
    2026, 31(9):  1275-1285.  doi:10.12092/j.issn.1009-2501.2026.09.014
    Asbtract ( 8 )   HTML ( 0)   PDF (606KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    This article focuses on the three major endocrine/neuroregulatory systems associated with hypertension—the renin-angiotensin-aldosterone system (RAAS), the hypothalamic-pituitary-adrenal axis (HPA axis), and the sympathetic nervous system (SNS)—to review modern research and ongoing controversies surrounding classical compound prescriptions (empirical formulas/classic prescriptions) and their active ingredients in the intervention of hypertension. The review emphasizes the pharmacological evidence pertaining to components such as flavonoids, alkaloids, and saponins, while also discussing the boundaries of the "TCM syndrome–endocrine marker" correspondence, the safety prerequisites for toxic components (e.g., aconitine), and the bottlenecks in clinical translation. Current evidence primarily consists of cell and animal studies, with high-quality randomized controlled trials remaining insufficient; therefore, future research should adopt more standardized study designs to enhance the level of evidence.

    Research progress in immunotherapy and emerging technologies for osteoarthritis
    Zishun GAO, Yunxia LI
    2026, 31(9):  1286-1296.  doi:10.12092/j.issn.1009-2501.2026.09.015
    Asbtract ( 5 )   HTML ( 0)   PDF (3208KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    Osteoarthritis (OA) is a chronic condition characterized by joint pain, functional impairment, and degeneration of articular cartilage. Currently, there remains a lack of effective treatments capable of altering the disease progression. In recent years, advances in immunology, molecular biology, stem cell technology, and genetic engineering have driven forward research on OA therapies. Although targeted agents and non-specific anti-inflammatory drugs have shown certain anti-inflammatory or analgesic effects in some clinical trials, their overall efficacy remains limited and safety concerns persist. Meanwhile, emerging approaches such as immunotherapy, cell-based therapy, and gene therapy offer novel strategies for OA intervention, showing potential advantages in suppressing inflammation, preserving cartilage, and alleviating pain. However, issues such as long-term safety, durability of therapeutic effects, and patient stratification require further clarification. In the future, OA treatment is expected to evolve toward precise phenotyping, combined interventions, localized long-term immunomodulation, and innovative drug delivery approaches. This review summarizes recent advances in the field to provide insights for optimizing future therapeutic strategies for OA.